Diabetes, obesity & metabolism|2025|Abouelmagd A et al.|1 citation
PMID: 40726455
A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
Obesity, a multifaceted and chronic condition characterized by excessive fat accumulation, poses significant risks to overall health and is associated with various metabolic and cardiovascular complications. This literature review evaluates and compa…
INTRODUCTION: GLP-1 receptor agonists (GLP1-RAs) are increasingly prescribed as an alternative to bariatric surgery for weight loss, and may pose as an alternative to conversion Roux-En-Y Gastric Bypass (cRYGB) in patients with insufficient weight lo…
OBJECTIVE: The hormone peptide YY (PYY; cleaved into Y-selective form PYY) is an attractive candidate for use as a complementary pharmacotherapy for obesity along with glucagon-like peptide-1 (GLP-1) receptor agonists. This series of studies investig…
Obesity is associated with an increased cardiovascular risk. Drugs with glucagon-like peptide-1 receptor agonist (arGLP-1) action for overweight/obesity, such as liraglutide, semaglutide, and tirzepatide, have shown improvements in weight and body co…
BACKGROUND: Incisional hernia repairs (IHRs) are not recommended in patients with severe obesity (BMI ≥ 35 kg/m). Weight loss is challenging, but new medications, such as glucagon-like peptide-1 receptor agonists (GLP-1 agonists), have recently attra…
Strategies to reduce weight in people living with obesity (PwO) include calorie restriction, metabolic and bariatric surgery (MBS), and anti-obesity drugs, including glucagon-like peptide-1 receptor agonists (GLP-1Ra). Although weight loss in PwO has…
BACKGROUND/OBJECTIVE: A patient with obesity, anxiety, depression, and hyperandrogenism, diagnosed with mild hypercortisolism of unknown etiology, had increased weight loss with the combination of levoketoconazole and semaglutide. CASE REPORT: A 21-y…
OBJECTIVE: Obesity affects more than 40% of US adults, increasing risks for cardiovascular disease and type 2 diabetes. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs), initially indicated for diabetes, show promise in weight loss but face cove…
BACKGROUND: Substance use disorders (SUDs) remain a major global health challenge with limited pharmacological treatment options and high relapse rates. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), originally developed for type 2 diabetes an…
BACKGROUND: The rising obesity rates in the USA have led to a surge in various weight loss treatments. Glucagon-like peptide-1 (GLP-1) analogues have shown promise in reducing weight but primarily studied in Caucasian populations. Sleeve gastrectomy…
PURPOSE: Dry eye disease (DED) is a prevalent ocular surface disorder frequently associated with type 2 diabetes mellitus (T2DM). While glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated systemic anti-inflammatory and vascular be…
AIMS: To explore the relationship between weight loss and insulin sensitivity in response to tirzepatide or semaglutide. MATERIALS AND METHODS: We conducted a post hoc exploratory analysis of a 28-week, double-blind, randomized trial in people with t…
Rhabdomyolysis is a clinical syndrome characterized by the breakdown of skeletal muscle, leading to the release of creatine kinase (CK), myoglobin and electrolytes into the circulation. This can result in acute kidney injury and other complications.…